Aclaris Announces Topline Results From 12-Week Phase 2b Trial Of Oral Zunsemetinib For Moderate To Severe Rheumatoid Arthritis; Study Did Not Meet Primary Or Secondary Efficacy Endpoints, Efficacy Results Do Not Support Further Development Of Zunsemetinib

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!